MedTech Atlas
Back to medical device regulatory guideAll countries
Asia PacificENPublic regulatory overview

Australia

Country Overview Population: Approximately 26.4 million (2024); population concentrated in four major metropolitan areas — Sydney, Melbourne, Brisbane, and Perth Healthcare system:...

Updated: 2026-05-04

You are viewing the public excerpt. During the limited-time free period, sign in to view the complete country report.

Sign in / register for full country report
Reference approval strategy

FDA / CE / MDSAP / NMPA benefits for this market

These factors can reduce evidence-building work, support review confidence, or shape the filing strategy. They do not automatically replace local registration.

US FDA

510(k) / De Novo / PMAStrong benefit

FDA evidence can materially improve review confidence and may support verification, abridged, or reliance-style pathways.

Likely benefit
  • Use FDA review summaries, clearance or approval letters, test reports, clinical evidence, and software or electrical-safety files as support.
  • May reduce technical questions when the intended use, model scope, and evidence package match the local filing.
Limit
  • Does not remove local holder, language, labeling, fee, import, or post-market obligations.
View topic

EU CE

MDR / IVDRStrong benefit

CE documentation is highly reusable and may support reference, reliance, or overseas conformity assessment routes.

Likely benefit
  • Reuse MDR/IVDR technical documentation, clinical evaluation, ISO testing, GSPR or essential-principles mapping, labeling, and PMS evidence.
  • Often helps build CSDT, IMDRF, or local-format technical files faster.
Limit
  • Does not replace local registration or local representative responsibilities outside the CE-recognized route.
View topic

MDSAP

Single QMS auditStrong benefit

MDSAP can reduce duplicate QMS audit burden and may be accepted as a substitute or strong audit evidence.

Likely benefit
  • Reduce duplicate quality-system audits and support ISO 13485, CAPA, complaints, supplier controls, design controls, and production controls.
  • Most useful when the market accepts MDSAP directly or when the application depends on QMS maturity.
Limit
  • Does not authorize product sale and does not replace safety, performance, or clinical evidence.
View topic

China NMPA

China registration / filingDossier reuse only

The NMPA certificate itself has limited effect, but ISO/IEC-aligned test reports, clinical evidence, risk files, and PMS data can be reused after gap assessment.

Likely benefit
  • Use NMPA approval as prior-registration evidence, China market history, and product-maturity support.
  • Convert ISO/IEC-aligned testing, clinical, risk-management, and PMS documents from the NMPA file into the local dossier.
Limit
  • Do not assume automatic recognition; China-only GB/YY evidence may need retesting or restructuring.
View topic

AI Citation Summary

  • Country: Australia
  • Product line: Medical devices
  • Regulator / source: Regulatory maturity: Extremely high. TGA (Therapeutic Goods Administration) is a globally recognized high-quality regulator with strong efficiency, transparency, and predictable review timelines. TGA is an active contributor to IMDRF (International Medical Device Regulators Forum), maintains close regulatory coordination with FDA, EMA, and Health Canada, and has one of the world's most systematized foreign regulatory recognition frameworks — the OCA (Overseas Conformity Assessment) system — which is the most important market entry accelerator for Australia.
  • Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
  • Typical timeline: Regulatory maturity: Extremely high. TGA (Therapeutic Goods Administration) is a globally recognized high-quality regulator with strong efficiency, transparency, and predictable review timelines. TGA is an active contributor to IMDRF (International Medical Device Regulators Forum), maintains close regulatory coordination with FDA, EMA, and Health Canada, and has one of the world's most systematized foreign regulatory recognition frameworks — the OCA (Overseas Conformity Assessment) system — which is the most important market entry accelerator for Australia.
  • Key fees: Market characteristics: Market size approximately AUD 8 billion (approximately USD 5.3 billion) in 2023. English-language market with relatively low entry barriers (no language labeling obstacles; culture closely aligned with Europe and the US). Import dependence is high (approximately 85% of devices are imported). Orthopaedic implants, cardiovascular devices, ophthalmic products, and diagnostic imaging are the four high-value categories. The Prostheses List (implants and prostheses covered by private health insurers) is the core procurement mechanism for private health insurance reimbursement.
  • Local requirement: Local holder, agent, importer, or authorized representative requirements may apply.
  • Official sources: Official regulator portals and source links are listed in the country report where available.
  • Last verified: 2026-05-04
  • Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
  • Preferred citation: MedTech Atlas

Country Overview

  • Population: Approximately 26.4 million (2024); population concentrated in four major metropolitan areas — Sydney, Melbourne, Brisbane, and Perth
  • Healthcare system: Universal Medicare (federally operated; covers inpatient care, basic outpatient services, and some diagnostic testing) supplemented by private health insurance (held by approximately 45% of the population, covering private hospitals, specialist consultations, and services not covered by Medicare). Private hospitals account for approximately 36% of total national beds and are a key channel for premium devices. PBAC (Pharmaceutical Benefits Advisory Committee) and MSAC (Medical Services Advisory Committee) evaluate reimbursement value for health technologies.
  • Market characteristics: Market size approximately AUD 8 billion (approximately USD 5.3 billion) in 2023. English-language market with relatively low entry barriers (no language labeling obstacles; culture closely aligned with Europe and the US). Import dependence is high (approximately 85% of devices are imported). Orthopaedic implants, cardiovascular devices, ophthalmic products, and diagnostic imaging are the four high-value categories. The Prostheses List (implants and prostheses covered by private health insurers) is the core procurement mechanism for private health insurance reimbursement.
  • Regulatory maturity: Extremely high. TGA (Therapeutic Goods Administration) is a globally recognized high-quality regulator with strong efficiency, transparency, and predictable review timelines. TGA is an active contributor to IMDRF (International Medical Device Regulators Forum), maintains close regulatory coordination with FDA, EMA, and Health Canada, and has one of the world's most systematized foreign regulatory recognition frameworks — the OCA (Overseas Conformity Assessment) system — which is the most important market entry accelerator for Australia.

Regulatory Authority

  • Primary authority: TGA (Therapeutic Goods Administration), under the federal Department of Health and Aged Care
  • Registration database: ARTG (Australian Register of Therapeutic Goods); all therapeutic products legally sold in Australia must be registered or listed in the ARTG
  • Official portal: https://www.tga.gov.au; Online application system: TGA Business Services (TBS) — https://www.tga.gov.au/tga-business-services
  • Key regulations:
    • Therapeutic Goods Act 1989 (TG Act — the primary federal statute)
    • Therapeutic Goods (Medical Devices) Regulations 2002 (TGMD Regulations)
    • Therapeutic Goods Regulations 1990 (supplementary provisions)
    • Essential Principles for Safety and Performance of Medical Devices (Schedule 1, TGMD Regulations; equivalent to EU MDR Annex I)
    • Conformity Assessment Procedures (Schedule 3, TGMD Regulations)
    • Therapeutic Goods (Medical Devices) Amendment (2022 Measures No. 2) Regulations 2022
    • TGA Guidance Documents series: https://www.tga.gov.au/resources/resource/guidance

In May 2026, TGA published a dedicated user guide for applications involving medical devices that do not meet UDI-related Essential Principles (EPs), alongside its UDI Consent to Supply (CtS) process. This is especially important for Class III and Class IIb devices because mandatory UDI compliance for high-risk devices starts on 1 July 2026. If a Sponsor cannot complete all UDI labelling, database, or direct marking requirements by the compliance date, the Sponsor should assess whether a UDI-related CtS application through TGA Business Services is required.

  • Scope: The streamlined pathway applies only where the application relates solely to UDI-related Essential Principles. If the same application includes both UDI and non-UDI EP non-compliance, the standard CtS process and standard fee apply.
  • Timing: The streamlined review process and reduced fee are not available for UDI CtS applications submitted before 1 July 2026. Sponsors should use the new mechanism from 1 July 2026.
  • Fees: TGA expects the UDI CtS fee to be AUD 80 for the first ARTG entry and AUD 10 for each additional ARTG entry in the same application, materially lower than ordinary CtS costs.
  • Regulatory position: TGA advises that Sponsors do not need to submit UDI CtS applications for Class III and Class IIb devices before 1 July 2026. Where Sponsors apply for UDI CtS from 1 July 2026 and import or supply devices during the period between application and consent grant, TGA does not intend to take regulatory action. TGA will review this position after approximately 2 months.
  • Submission focus: Sponsors should prepare the UDI non-compliance explanation, affected ARTG entries, remediation strategy, expected completion dates, and continued-supply rationale. Non-UDI labelling, performance, safety, or other EP issues should not be combined into a UDI-only application.
  • Official sources: TGA UDI CtS process (updated 7 May 2026) and "Completing an application for consent to import, supply or export medical devices that do not meet UDI-related Essential Principles" (published 20 May 2026).

Device Classification System

Local Class Risk Level Approximate EU Equivalent Notes
Class I Lowest risk EU Class I (non-sterile/non-measuring) Typical: general examination gloves, general non-sterile devices
Class Is Low risk (sterile) EU Class I sterile Sterilization conformity evidence required; typical: sterile wound dressings, sterile gloves
Class Im Low risk (measuring) EU Class I measuring Devices with a measuring function; typical: thermometers, some blood pressure monitors
Class IIa Low-Moderate risk EU Class IIa Typical: diagnostic ultrasound, vascular catheters, contact lenses
Class IIb Moderate-High risk EU Class IIb Typical: ventilators, orthopaedic fixation implants, infusion pumps
Class III High risk EU Class III Typical: heart valves, vascular stents, absorbable implants
AIMD High risk (active implantable) EU AIMD Typical: pacemakers, implantable defibrillators, cochlear implants

Classification mechanism: Based on GHTF/IMDRF classification principles, closely aligned with the EU MDR classification system. Australian and EU classification for the same product typically coincides — providing a strong basis for the OCA pathway using EU CE certificates. The TGA Medical Device Classification Tool is available on the TGA website.

IVD separate classification: In vitro diagnostic devices (IVD) are classified under the Therapeutic Goods (Medical Devices) Amendment (In Vitro Diagnostic Devices) Regulations 2010 (Class 1–4, independent of the above classification system) and have a dedicated ARTG application process.

Registration Pathways

During the limited-time free period, sign in or register to view the complete medical device country report.